SureTrader SureTrader SureTrader
Home > Boards > US Listed > Biotechs >

MultiCell Technologies (MCET)

MCET RSS Feed
Add MCET Price Alert      Hide Sticky   Hide Intro
Moderator: MyDogBuster, Dip66, simon wagstaff
Search This Board:
Last Post: 1/18/2017 10:59:44 AM - Followers: 549 - Board type: Free - Posts Today: 7

 

MultiCell Technologies, Inc. (MCET)

U.S. Reporting: SEC Filer 

Office: (401) 762-0045  |  Email: [email protected]  |  Web: www.MultiCellTech.com

(This "Intro Box" is NOT maintained by MultiCell Technologies and is intended solely as a quick information source on ihub.  For more detailed, up-to-date information on MultiCell Technologies,  please go the company website.)


Partners

AmarinCorningPhizer

 

MultiCell inks R&D agreement with Oxis Biotech

MultiCell Technologies (OTCPK: MCET) subsidiary MultiCell Immunotherapeutics enters into a research and development and product license agreement with Oxis Biotech (OTCQB: OXIS)
to create three novel antibody-drug conjugates (ADCs) based on Oxis' lead drug candidates and MultiCell's proprietary ADC platform technology. The ADCs will be targeted for the treatment
of triple-negative breast cancer and multiple myeloma and associated osteolytic lesions.

MultiCell retains all rights to its ADC platform for all indications and is free to pursue its own drug development programs and to partner with other firms.

Patent Portfolio of MultiCell Technologies, Inc., MultiCell Immunotherapeutics and majority-owned subsidiary, Xenogenics. Patents already published which can be found in the public domain.







Xenogenics Corporation

Xenogenics Corporation (“Xenogenics”), a development-stage medical device company, is focused on the design of next-generation bioabsorbable stents for interventional cardiology
and peripheral vascular applications. Xenogenics is a majority owned subsidiary of MultiCell Technologies, Inc. (OTCBB: MCET).

 

Xenogenics' Ideal BioStent™ is a bioabsorbable stent which incorporates Rapamycin providing anti-restenotic therapy similar to today's commonly used drug-eluting metal stents.  
Xenogenics' bioabsorbable stent technology allows for the ability to layer different combinations of polymers and drugs, enabling the optimization of the delivery of combination drug therapies to provide
superior clinical results.  Xenogenics' Ideal BioStent™ represents a significant advance over currently available stents, including:

* The ability to promote positive vessel remodeling.
* No metal artifact remaining in the patient's body after vessel healing.
* The reduced need for long-term and costly anti-platelet therapy.




 









 

MultiCell Technologies, Inc. Corporate Headquarters


MultiCell Technologies, Inc.
68 Cumberland Street, Suite 301

Woonsocket, RI 02895


MultiCell Technologies, Inc. is a clinical-stage biopharmaceutical company developing novel therapeutics and discovery tools that address unmet medical needs for the treatment of neurological disorders, hepatic disease and cancer.

Our therapeutic development platform relies on several patented technologies used to: (i) isolate, characterize and differentiate stem cells from human liver, or (ii) control the immune response at transcriptional and translational levels through dsRNA-sensing molecules such as Toll-like receptor (TLR), RIG-I-like receptor (RLR), and MDA-5 signaling, or (iii) generate specific and potent immunity against key tumor targets through a novel immunoglobulin platform technology, or (iv) modulate the noradrenaline-adrenaline neurotransmitter pathway.

Our most advanced lead drug candidate, MCT-125, is an oral small molecule drug combination which targets the noradrenaline-adrenaline neurotransmitter pathway for the treatment of primary multiple sclerosis-related fatigue (PMSF). Primary multiple sclerosis-related fatigue (PMSF) affects over 70% of all persons with multiple sclerosis (MS). MCT-125 has demonstrated efficacy in a 138 patient Phase 2a clinical trial for the treatment of PMSF.

While significant progress has been made in developing cancer therapies that result in tumor regression, the control of cancer over a longer interval and especially of metastatic disease, remains a key goal. MultiCell is also developing novel therapeutics for the treatment of cancer. MCT-465, MCT-475 and MCT-485 are the first of a family of prospective cancer therapeutics based on the use of our patented therapeutic antibody and synthetic dsRNA technologies. MCT-465, a potent immune enhancer, is indicated as an cancer adjuvant therapy alone or combined with currently available or novel therapies. MCT-465 can also be used with our MCT-475 antibody therapeutic for the treatment of various cancers such as breast carcinoma. MCT-485, a cytotoxic agent, is a novel synthetic dsRNA with therapeutic properties distinct from those of MCT-465, and is indicated for the treatment of certain cancers. MCT-465 is in early-stage preclinical development, and MCT-475 and MCT-485 are in the discovery optimization stage of development.

The role liver stem cells play in the carcinogenic process has recently led to a new hypothesis that hepatocellular carcinoma arises by maturation arrest of liver stem cells. MultiCell is developing therapeutic product opportunities specifically targeting the treatment of hepatocellular carcinoma and intrahepatic bile duct cancer by leveraging our synthetic dsRNA and antibody therapeutic platforms against cancer stem cells. MultiCell owns exclusive rights to two issued U.S. patents (6,872,389 and 6,129,911), and several corresponding issued and pending patents and patent applications related to the isolation and differentation of liver stem cells.
 






 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MCET
Current Price
Volume:
Bid Ask Day's Range
SureTrader
MCET News: Termination of Registration of a Class of Security Under Section 12(g) (15-12g) 01/13/2017 06:03:38 AM
MCET News: Current Report Filing (8-k) 09/26/2016 04:12:21 PM
PostSubject
#42498  Sticky Note Global Bioabsorbable Stents Market to Reach $2.4 Billion Dip66 01/05/17 08:45:10 AM
#42250  Sticky Note MultiCell $MCET mentioned in this new report. Dip66 12/19/16 03:41:53 PM
#42563   Maybe somebody needs to call MCET and get simon wagstaff 01/18/17 10:59:44 AM
#42562   Always good for a laugh. simon wagstaff 01/18/17 09:15:33 AM
#42561   This stock will start seeing more volume - BCLBCL 01/18/17 09:07:16 AM
#42560   You should! Major news will hit soon enough! BCLBCL 01/18/17 09:05:38 AM
#42559   You already got your major news, MCET going simon wagstaff 01/18/17 08:35:20 AM
#42558   Bought a few more yesterday & last week... BCLBCL 01/18/17 07:40:06 AM
#42557   I remember when penny stock junkies couldn't stop Murph32 01/18/17 05:12:28 AM
#42556   thank you Zollo for responding to bontooth 01/15/17 03:23:26 AM
#42555   Simon bontooth 01/15/17 03:15:29 AM
#42554   zero position. bontooth 01/15/17 02:58:32 AM
#42553   Simon, an ex-employee can only hold a grudge Dip66 01/15/17 12:42:01 AM
#42552   Looking forward to $MCET this year. Dip66 01/15/17 12:40:46 AM
#42551   OK, this is pretty funny too. simon wagstaff 01/14/17 05:46:46 PM
#42550   OXIS INTERNATIONAL INC - FORM S-1/A - EX-10.6 TPX 01/14/17 04:01:28 PM
#42549   Multicell and Oxis MERGER? TPX 01/14/17 03:51:15 PM
#42548   Research Insights on Liver Cancer - Pipeline Review, TPX 01/14/17 03:43:13 PM
#42547   People? One full time employee. simon wagstaff 01/14/17 02:05:00 PM
#42546   Read their Facebook message, delisting jeffshir 01/14/17 12:50:00 PM
#42545   Tk hope you are right. Sometimes the news The dead cat bouncer 01/14/17 11:36:38 AM
#42544   So far we have not made any money The dead cat bouncer 01/14/17 11:34:07 AM
#42543   At any point in time MCET has been simon wagstaff 01/14/17 11:27:46 AM
#42542   Hi Bontooth, I post from my heart. My Zollo 01/14/17 10:55:04 AM
#42541   Again Simon, what's your motive here? Penny Zollo 01/14/17 10:43:48 AM
#42540   Depends on if you prefer fake news or simon wagstaff 01/14/17 08:57:44 AM
#42539   Wow .. . bontooth 01/14/17 03:04:44 AM
#42538   thanks you d.c 'bouncer bontooth 01/14/17 02:51:16 AM
#42537   Great post and looking forward to a new Dip66 01/14/17 02:26:24 AM
#42536   Simon, I am curious why you are always Zollo 01/13/17 04:28:40 PM
#42535   Now that the MCET story is gasping to simon wagstaff 01/13/17 11:57:14 AM
#42534   $2,600 is interesting? simon wagstaff 01/13/17 11:56:00 AM
#42533   13,000,000 shares bought up getting interesting. $MCET Dip66 01/13/17 11:40:09 AM
#42532   Yes, now you lie about anything! Not that simon wagstaff 01/13/17 09:57:07 AM
#42531   So the fact that they are NO LONGER ctvette2003 01/13/17 09:51:37 AM
#42530   And this is good why? Cant wait for ctvette2003 01/13/17 09:45:18 AM
#42529   So this is good? What am I missing? ctvette2003 01/13/17 09:31:22 AM
#42528   Nothing like going dark to instill investor confidence. LeGoose 01/13/17 09:06:54 AM
#42527   Agree! Bio trip stocks are rare! & eventually BCLBCL 01/13/17 07:48:56 AM
#42526   Major news to hit soon! Filing just released... BCLBCL 01/13/17 07:47:21 AM
#42525   Interesting! There is some life in this severely BCLBCL 01/13/17 07:46:37 AM
#42524   Filing out! Termination of Registration of a Class TPX 01/13/17 06:58:29 AM
#42523   Hey TPX is this the news you wanted ctvette2003 01/13/17 06:08:16 AM
#42522   http://www.occmd.org/webcn2016/ppt/pdf/0033.pdf TPX 01/12/17 08:33:32 PM
#42521   We also made this European Medical Journal. The dead cat bouncer 01/12/17 08:07:36 PM
#42520   I found this in a medical journal. The dead cat bouncer 01/12/17 08:00:23 PM
#42519   TPX - Still holding true to your word Dip66 01/12/17 09:45:07 AM
#42518   Yes gold does not go bankrupt. If you The dead cat bouncer 01/11/17 11:10:23 AM
#42517   I said some prayers for your family The dead cat bouncer 01/11/17 11:05:07 AM
#42516   Currently, there are no FDA approved drugs for bontooth 01/10/17 11:34:09 PM
#42515   Really? 30 bucks today? Somebody knows something. simon wagstaff 01/10/17 07:51:46 PM
#42514   Until then buy gold. The dead cat bouncer 01/10/17 01:52:54 PM
PostSubject